US FDA Approves Pfizer’s Blood Cancer Therapy

(Reuters) -The U.S. Meals and Drug Administration on Monday granted accelerated approval to Pfizer’s remedy for treating sufferers with a sort of blood most cancers that’s troublesome to deal with, the corporate stated.

The well being regulator’s resolution permits use of the remedy, branded as Elrexfio, in sufferers with a number of myeloma that’s arduous to deal with or has come again after receiving 4 or extra prior strains of sure lessons of therapies.

Elrexfio, or elranatamab, is run below the pores and skin and belongs to a category of therapies generally known as bispecific antibodies, that helps the physique’s immune system to kill cancerous cells by bringing a most cancers cell and an immune cell collectively.

Pfizer has stated the remedy might have greater than $4 billion in potential peak income.

(Reporting by Bhanvi Satija and Leroy Leo in Bengaluru; Modifying by Shounak Dasgupta)

Copyright 2023 Thomson Reuters.